On March 12, YIDU TECH (02158) executed another share repurchase, spending over HK$10 million on the day. This brings the total number of buybacks for the year to 28, with cumulative expenditures exceeding HK$1.9 billion. The company's high-frequency and sustained capital actions strongly demonstrate management's firm confidence in the company's long-term intrinsic value and the growth prospects of the AI healthcare industry. These moves also convey a positive signal to the market about the robustness of the company's fundamentals and its promising future growth trajectory.
Recently, YIDU TECH launched its significant new product, the "Yidu Zhi Xun" clinical evidence-based intelligent agent. This AI product, designed specifically for clinicians and medical researchers, addresses core challenges in diagnosis, treatment, and scientific research. It leverages a massive, high-quality knowledge base built from authoritative medical guidelines and literature. The system enables traceability of clinical decision evidence and provides precisely tailored diagnostic and treatment recommendations, filling a gap in the field of clinical evidence-based AI and further enhancing the company's portfolio of clinical intelligence products.
It is reported that "Yidu Zhi Xun" is grounded in a rigorous evidence-based evaluation system. It meticulously selects over 30,000 authoritative entries from more than 40,000 guidelines and over 5 million high-quality research findings from a pool exceeding 30 million documents. The knowledge base is constructed in collaboration with authoritative institutions, including the People's Medical Publishing House, and continuously integrates the latest research from top-tier journals such as NEJM, The Lancet, and JAMA. A core capability of the system is its transparency in the AI generation process; every conclusion is linked to a clear source, allowing doctors to verify original materials with a single click. The system ranks answers based on the GRADE evidence hierarchy, facilitating more precise decision-making.
Notably, "Yidu Zhi Xun" incorporates a multi-specialty intelligent agent distribution engine. This engine can intelligently identify the specialty attribute and clinical intent of a query, automatically routing it to the corresponding specialist agent. Furthermore, YIDU TECH recently engaged in deep discussions with local authorities in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan. Building on its core technologies in medical big data and AI-assisted diagnosis and treatment, the company is deepening practical cooperation. It had previously played a significant role in developing Lecheng's real-world research platform, aiding in the accelerated introduction of innovative drugs and medical devices. The company is also actively advancing grassroots medical digitalization projects in Hainan, unlocking key scenarios for the commercialization of AI healthcare.
On one front, continuous share buybacks are reinforcing confidence; on another, innovative products are being deployed to realize value. YIDU TECH is steadily building its core competitive advantages during a period of accelerated AI healthcare commercialization, with its long-term growth drivers continuously strengthening.